SJF Pharmaceuticals

The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
Sacramento Bee, CA
Sat, 09/8/12 - 11:28 am
non-small cell lung cancer
dacomitinib
SJF Pharmaceuticals
Pfizer